Accueil
mcv4
Illustration of time at risk of IMD, MCV4 vaccination uptake and

Illustration of time at risk of IMD, MCV4 vaccination uptake and

4.8 (796) · € 25.99 · En Stock

Download scientific diagram | Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied. IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine from publication: Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine | In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended | Meningococcal Vaccines, Conjugate Vaccines and Vaccines | ResearchGate, the professional network for scientists.

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. - Abstract - Europe PMC

Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010, BMC Infectious Diseases

Meningococcal Vaccines Market Size & Share Report, 2030

Epidemiology of invasive meningococcal disease in Greece, 2006–2016

Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors, Epidemiology & Infection

Vaccines, Free Full-Text

Full article: Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada